Evonik’s TROGAMID® T5000: making eyewear lighter, stronger and more efficient
TROGAMID® T5000, a semi-crystalline polyamide with a transparency of 90%, is an ideal material for optical manufacturers. Compared to other transparent polyamides, TROGAMID® T5000offers higher modulus and rigidity. Moreover, the material is especially suitable for manufacturing thin frames and semi-rimless eye wear frames, which can significantly reduce the frame weight without affecting performance. This in turn greatly improves wearing comfort.
Lighter, stronger and more efficient
Lightweight design plays an important role in many sectors, but is particularly relevant for the optical industry. The high strength and rigidity of TROGAMID® T5000enables the production of thinner and lighter eye wear frames. Additionally, TROGAMID® T5000 is more resilient than heavier conventional frames, which translates into greater freedom for designers.
While consumers tended to focus on aesthetics in the past, they now place greater emphasis on product quality and performance. Optical manufacturers carefully consider material properties for their choices. TROGAMID® T5000 is characterized by its outstanding chemical resistance, which prevents cracking from contact with chemicals. Furthermore, the material’s easy processing and coloring properties save time and money for maximum efficiency.
Cooperation of Evonik and Hwa Mao Optical (Xiamen)
This application was developed and implemented as part of a cooperation between Evonik and Hwa Mao Optical (Xiamen).
Hwa Mao Optical (Xiamen) Co., Ltd., established in 1996, specializes in manufacturing a wide variety of eyewear products.
Learn more about high-performance plastic TROGAMID® for optical applications at our booth (1E-D12) at the Optical Fair, November 08–10, in Hong Kong.
Capture: TROGAMID® T5000: making eyewear lighter, stronger and more efficient
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2016 the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.
Evonik’s international activities are organized into six regions. The Asia Pacific North region consists of China, Taiwan, Japan & Korea, and is headquartered in Shanghai. Sales in Asia Pacific North reached 1,947 million euros in 2016. Evonik regards China as one of the driving forces of the global economy and we consequently endeavour to grow our business here. The company now employs about 3,000 employees and has in total of 10 production sites in China.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.